<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As a DNA repair protein, Flap endonuclease 1 (FEN1) plays crucial parts in preventing <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Two functional germ line variants (-69G &gt; A and 4150G &gt; T) in the FEN1 gene have been associated with DNA damage levels in coke oven workers and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> risk in general populations </plain></SENT>
<SENT sid="2" pm="."><plain>However, the role of these genetic variants on <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> susceptibility is unknown </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we evaluated the association between these polymorphisms and <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> risk in two independent case-control cohorts consisted of a total of 1850 gastrointestinal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (<z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) patients and 2222 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>The impact of these variations on FEN1 expression was also examined using liver, esophagus, stomach and colon <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="5" pm="."><plain>It was found that the FEN1 -69GG genotypes were significantly correlated to increased risk for developing <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> compared with the -69AA genotype in both cohorts [Jinan cohort: odds ratios (OR) = 2.14, 95% confidence interval (CI) = 1.47-2.80, P = 1.0 × 10(-)(6); Huaian cohort: OR = 1.93, 95% CI = 1.37-2.50, P = 0.5 × 10(-6)] </plain></SENT>
<SENT sid="6" pm="."><plain>Similar results were observed for 4150G &gt; T polymorphism </plain></SENT>
<SENT sid="7" pm="."><plain>In the combined meta-analyses, OR for -69GG or 4150GG genotype was 2.02 (95% CI = 1.59-2.45) or 1.86 (95% CI = 1.45-2.28) compared with -69AA or 4150TT genotype </plain></SENT>
<SENT sid="8" pm="."><plain>In vivo FEN1 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> expression analyses showed that the -69G or 4150G allele carriers had ∼2-fold decreased FEN1 expression in gastrointestinal tissues compared with -69A or 4150T carriers, indicating that lower FEN1 expression may lead to higher risk for <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of gastrointestinal cells </plain></SENT>
<SENT sid="9" pm="."><plain>Our results highlight FEN1 as an important gene in human gastrointestinal <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> and genetic polymorphisms in FEN1 confer susceptibility to <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e> </plain></SENT>
</text></document>